Europace

Europace Advance Access originally published online on February 14, 2006
Europace 2006 8(3):157-160; doi:10.1093/europace/euj042

This Article Abstract FREE Full Text (PDF) All Versions of this Article: 8/3/157    most recent euj042v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Goette, A. Articles by Auricchio, A. Search for Related Content PubMed PubMed Citation Articles by Goette, A. Articles by Auricchio, A. Social Bookmarking          What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

---

CRT

Cardiac uptake of progenitor cells in patients with moderate-to-severe left ventricular failure scheduled for cardiac resynchronization therapy

Andreas Goette^1,*, Kathleen Jentsch-Ullrich², Matthias Hammwöhner¹, Silke Trautmann¹, Astrid Franke², Helmut U. Klein¹ and Angelo Auricchio¹

¹ Division of CardiologyUniversity Hospital MagdeburgLeipziger Street 44, 39120 Magdeburg Germany ; ² Division of Hematology/OncologyUniversity Hospital MagdeburgMagdeburg Germany

Manuscript submitted 7 May 2004. Accepted after revision 18 October 2005.

^* Corresponding author. Tel: +49 391 6713203; fax: +49 391 6713202. E-mail address: andreas.goette{at}medizin.uni-magdeburg.de

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
Aims Injury to the heart causes haematopoietic and endothelial progenitor cells (PCs) to migrate to the site of damage and to undergo PC differentiation, which may contribute to angiogenesis and myocardial tissue repair. We sought to determine the cardiac uptake of PC in patients with moderate-to-severe congestive heart failure (CHF) scheduled for cardiac resynchronization therapy.

Methods and results A total of 28 patients was included in the study. Fourteen patients had moderate-to-severe CHF with a mean left ventricular ejection fraction (LVEF) of 20±9%. The remaining patients had a normal LVEF and served as controls. PCs (CD34⁺ and CD34⁺/CD117⁺) were quantified using a fluorescence-activated cell sorter. In CHF patients, PCs were determined from whole blood samples taken from the aorta, the coronary sinus (CS), and the superior vena cava (SVC) during right and left heart catheterization. Cardiac PC uptake was determined as the difference in PC levels between the aorta and the CS. Differences in CD34⁺PC counts (0.11±0.98x10³ mL^–1) and relative amount of CD34⁺/CD117⁺PC (0.08±0.31%) between the aorta and the CS were not significant. PC levels were comparable between the SVC, CS, and aorta. CD34⁺ and PC levels did not correlate with New York Heart Association class (r²=0.22), LVEF (r²=0.01), LV diameter (r²=0.05), QRS complex duration (r²=0.1), or maximal O₂ uptake during exercise (r²=0.08). There was no difference between patients with ischaemic cardiomyopathy (ICM) and non-ICM. Systemic PC levels were not different compared with age-matched controls without LV failure (CD34⁺: 4.61±1.83x10³ mL^–1 vs. control: 5.25±1.67x10³ mL^–1; P=n.s.).

Conclusion Moderate-to-severe chronic CHF is not associated with elevated PC levels in the systemic circulation. A measurable cardiac uptake of CD34⁺ and CD34⁺/CD117⁺PC cannot be demonstrated by FACS analysis in this cohort of patients.

Key Words: Blood, Cardiac catherization, Heart failure, Progenitor cells

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
Recent studies suggest that acute injury to the heart causes haematopoietic and endothelial progenitor cells (PCs) to migrate to the site of damage and to undergo PC differentiation.^1,2 Multipotent PCs, which are characterized by the cell-surface expression of CD34⁺ and CD117⁺, seem to be involved in neoangiogenesis and they may differentiate/transdifferentiate into cardiomyocytes.^1–4 Thus, PCs appear to have the potential to improve cardiac performance after an acute cardiac injury.^1,4 In contrast to acute cardiac injuries, the regulation of PC in patients with chronic stable cardiac abnormalities has not yet been analysed. Although it may be of great clinical relevance, the impact of moderate-to-severe stable congestive heart failure (CHF) on PC is unknown.

The purpose of the present study was to determine the amount of PC in patients with moderate-to-severe CHF. Therefore, venous and arterial PC levels were measured and the cardiac uptake of CD34⁺PC and CD34⁺/CD117⁺PC was assessed during cardiac catherization scheduled for cardiac resynchronization therapy.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
Patients
A total of 28 patients was included in the study. Fourteen patients (59±14 years, 11 men, 3 women) had symptomatic moderate-to-severe left ventricular failure [New York Heart Association (NYHA) classII], sinus rhythm, and depressed left ventricular ejection fraction (LVEF: 20±9%) despite pharmacological therapy (Table 1). The patients with CHF were referred to our institution for evaluation of non-pharmacological therapy of heart failure. In patients with CHF, blood samples were drawn during diagnostic right and left heart catheterization. Venous CD34⁺ and CD34⁺/CD117⁺PC levels of these patients were compared with 14 age-matched patients (55±16 years; eight men, six women) without structural heart or coronary artery disease. Nine patients (65%) had a history of hypertension, treated with ACE-inhibitors (53%), beta-blockers (47%), and calcium channel antagonists (18%). None of the included patients was taking statins at the time of the study. All patients gave informed consent to the procedure, which was performed according to the institutional guidelines of good clinical practice.

View this table: [in this window] [in a new window]   Table 1 CHF patients characteristics

 
Cardiac catheterization
Before performing a right and left cardiac catheterization as well as coronary angiography in a standard manner, in all patients, the coronary sinus (CS) was cannulated with an 8F CS-MP Easytrak guiding catheter (Guidant Corp., St Paul, MN, USA) inserted through the right jugular vein. While the guiding catheter was in the middle of the CS, 5 mL blood sample was withdrawn simultaneously with blood samples taken from the aortic root (via a 6F standard pigtail catheter) and from the superior vena cava (SVC) through the 8F sheath.

CD34⁺/CD117⁺ analysis
Analysis of PC was performed according to the recent publications.^5–7 In brief, each of 50 µL EDTA–blood samples was incubated with a nucleic acid dye, CD45-PerCP and CD34-PE (ProCOUNT CD34 reagent, BD-Immunocytometry Systems, San Jose, CA, USA) in bead-containing TRUCOUNT tubes (BD). The control reagent (nucleic acid dye, 1-PE and CD45-PerCP) was used to assess the amount of non-specific antibody binding. After red cell lysis with diluted fluorescence-activated cell sorter (FACS) lysing solution (BD), the samples were measured with an FACS Calibur flow cytometer (BD). The absolute number of CD34⁺ cells in the sample was determined by dividing the number of CD34⁺ cellular events by the number of fluorescent bead events and then multiplying with the bead concentration. The ProCOUNT software system (BD) was used to acquire and analyse data.

For CD34⁺/CD117⁺ quantification, 50 µL peripheral blood samples were labelled with FITC-CD34 and PE-CD117 (BD). After red cell lysis, flow cytometric analyses were performed on an FACS Calibur analytical flow cytometer (BD). List mode data were acquired by employing the CellQuest software (BD). Because of the low absolute number of CD34⁺/CD117⁺ cells, relative amounts of CD34⁺/CD117⁺ cells with regard to total leucocyte count were calculated. The coefficient of variation for CD34⁺PC measurements was <10%. All analyses regarding PC counting were performed in the Department of Haematology, University Hospital Magdeburg (certified laboratory by the German Accreditation Council and by the German Accreditation Body Chemistry), according to the European DIN EN ISO 15189.

Spiroergometry
Symptom-limited (fatigue or dyspnoea) metabolic stress testing was performed in eight patients with moderate-to-severe CHF, as previously described,⁸ on an upright bicycle ergometer, with a 10 W/min step protocol, starting with 2 min of unloaded cycling and recorded on a cardiopulmonary system (Oxycon Alpha, Jaeger, Wurzburg, Germany). Briefly, ventilation threshold was measured by the V-slope method if possible, otherwise, by inspection of ventilation equivalents.⁹ Peak VO₂ was defined as the highest VO₂ during any stage that could be sustained for 1 min; in most instances, this corresponded to the highest workload that was sustained for 1 min (i.e. peak workload). Peak VO₂ is reported after correction of body weight (mL/min/kg) and as a percentage of predicted normal values accounting for age, weight, and sex.

Statistical analysis
All values are expressed as mean±standard deviation. The paired and unpaired Student's t-test was used to assess differences in cell levels. Pearson's correlation coefficient (r²) was used to demonstrate the correlation between variables. A value of P<0.05 was considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
Baseline characteristics of the patients with CHF are shown in Table 1. In these patients, CD34⁺ and CD34⁺/CD117⁺PC levels were comparable at the different sample sites (Table 2). Importantly, no significant reduction of CD34⁺ and CD34⁺/CD117⁺PC could be detected in the CS compared with the aorta (Figure 1, Table 2). The relative amounts of CD34⁺/CD117⁺PC were very low in all patients. There was no difference between patients with ischaemic cardiomyopathy (ICM) and non-ICM (CD34⁺ ICM: 3.6±1.2x10³ mL^–1 vs. dilated cardiomyopathy (DCM): 4.4±0.9x10³ mL^–1 and CD34⁺/CD117⁺ ICM: 0.37±0.27% vs. DCM: 0.28±0.23%; P=n.s.). No relationship was found between medical therapy and CD34⁺ and CD34⁺/CD117⁺PC levels.

View larger version (13K): [in this window] [in a new window]   Figure 1 CD34+PC levels in the aorta and CS (differences were not significant; n=14).

 

View this table: [in this window] [in a new window]   Table 2 Cardiac PC level at different sites

 
Levels of CD34⁺ and CD34⁺/CD117⁺PC did not correlate significantly with clinical parameters such as age (CD34⁺: r²=0.14; CD34⁺/CD117⁺: r²=0.02; P=n.s.), height (CD34⁺: r²=0.03; CD34⁺/CD117⁺: r²=0.02; P=n.s.), NYHA class (CD34⁺: r²=0.22; CD34⁺/CD117⁺: r²=0.05; P=n.s.), LVEF (CD34⁺: r²=0.01; CD34⁺/CD117⁺: r²=0.12; P=n.s.), LV diameter (CD34⁺: r²=0.05; CD34⁺/CD117⁺: r²=0.1; P=n.s.), mean heart rate (CD34⁺: r²=0.08; CD34⁺/CD117⁺: r²=0.002; P=n.s.), systolic blood pressure (CD34⁺: r²=0.03; CD34⁺/CD117⁺: r²=0.01; P=n.s.), maximal O₂-uptake on spiroergometry (CD34⁺: r²=0.08; CD34⁺/CD117⁺: r²=0.28; P=n.s.), and QRS duration (CD34⁺: r²=0.1; CD34⁺/CD117⁺: r²=0.08; P=n.s.). Mean maximal O₂-uptake during exercise was 13±2 mL/min/kg in this group of patients (n=8).

Venous CD34⁺ and CD34⁺/CD117⁺PC levels were not different in patients with CHF compared with age-matched controls (CD34⁺level: 4.61±1.83x10³ mL^–1 vs. control: 5.25±1.67x10³ mL^–1; CD34⁺/CD117⁺: 0.36±0.35% vs. control: 0.28±0.21%; P=n.s.).

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
To the best of our knowledge, this is the first study analysing the potential cardiac uptake of CD34⁺ and CD34⁺/CD117⁺PC in patients with moderate-to-severe CHF. The main finding of our study is that CD34⁺ and CD34⁺/CD117⁺PC levels are not significantly reduced in the CS compared with the aorta, which demonstrates that there is no measurable cardiac uptake of CD34⁺ and CD34⁺/CD117⁺PC. In addition, systemic levels of CD34⁺ and CD34⁺/CD117⁺PC are not significantly altered in patients with chronic stable CHF compared with age-matched controls. Importantly, venous and arterial levels of CD34⁺ and CD34⁺/CD117⁺PC are not significantly different, which shows that venous blood samples are a robust measure for systemic PC levels.

Recent reports suggest that blood levels of CD34⁺PC increase in response to cardiac injury.^1,2 Chemokines such as the stromal cell-derived factor-1 and the vascular endothelium growth factor modulate the homing of PC in the bone marrow, and overexpression of these factors results in mobilization of PC in vivo.^1,10 Especially during myocardial ischaemia, CD34⁺/CD117⁺cells are increased.⁴ In this setting, the PC population seems to be involved in neoangiogenesis.¹ Kocher et al.¹ have demonstrated that venous injections of CD34⁺/CD117⁺PC result in an increased LVEF and increased amounts of myocardial capillaries in a myocardial infarction model. Besides ventricular ischaemia, vascular trauma, application of direct current shocks, etc. also influence systemic PC levels.^6,11,12 Furthermore, CD34⁺PC levels are increased in the blood of patients with persistent atrial fibrillation.⁶ The importance of atrial abnormalities on systemic PC was introduced by Quaini et al.² They have demonstrated a high proportion of PC in atrial tissue compared with ventricular myocardium.² However, the source of the demonstrated primitive cells remained unclear and early indicators of bone marrow cell differentiation were not found. Thus, myocardial uptake of CD34⁺PC from the systemic circulation may occur to only a very limited extent in the ventricles. This may help to explain the negative results of the present study, because the potential uptake of PC at the atrial level might be missed in blood samples taken from the CS. Furthermore, recent studies have assessed cardiac PC uptake using ¹¹¹indium oxide-labelled PC in a rodent infarct model.^13,14 Importantly, the amount of radioactivity in the whole heart was only 1% of the injected activity, which correlated to 1x10⁴PC. In contrast to the low cardiac uptake, scintigraphic images showed a significant lung uptake (17%) and a very high uptake by the liver and spleen (57%).¹³ This study suggests that left ventricular PC uptake is <1% even after application of high amounts of PC.

A recent study by Hofmann et al.¹⁵ showed that intravenous injections of unselected bone marrow cells (5% of these cells were radiolabelled with ¹⁸F-FDG) does not cause increased PC activity in the infarcted human heart. Even after intracoronary injection of unselected bone marrow cells, 1.3–2.6% of radiolabelled cells became detectable in the infarcted myocardium after 60 min. Thus, these results also suggest that the intrinsic capacity for cardiac PC uptake from the blood is limited. In a clinical setting, FACS analysis appears as the most relevant technique for CD34⁺PC counting. Nevertheless and in contrast to more sensitive ¹⁸F-FDG-labelling techniques, relative differences in PC levels 1% are not detectable using FACS analysis, although an absolute reduction of 1x10⁴PC would reliably be detected.

In the present study, absolute amounts of CD34⁺ and CD34⁺/CD117⁺PC were relatively low (4x10³ mL^–1) in patients with CHF with no difference from patients with normal LV function. Therefore, chronic moderate-to-severe CHF appears to be an insufficient stimulus to increase systemic PC levels and to induce a measurable cardiac PC uptake. Interestingly, clinical variables such as NYHA class, LVEF, LV diameter, etc. did not predict PC levels in our cohort of patients. This is further supported by the recent finding that amounts of CD34⁺ cells are significantly reduced in patients with decompensated heart failure (NYHA class IV).¹⁶ Experimental and clinical studies have revealed so far that large amounts of PC have to be injected/infused to induce modest improvements in ventricular performance.^1,13,15,17 Thus, spontaneous uptake of very small amounts of circulating PC by the left ventricle, even if present, might have no clinical benefit. Our study demonstrates by using FACS analysis the absence of a relevant cardiac uptake of circulating PC in patients with stable CHF. Thus, the combination of reduced amounts of circulating PC in severe heart failure and no or minimal PC uptake by the left ventricle supports the clinical knowledge that left ventricular failure is a progressive disease with no spontaneous recovery. Nevertheless, PC may reside in the adult heart and co-localize with small capillary vessels, which questions the relevance of circulating PC.

The injection of PC, however, into the myocardium or into the coronary arteries has been shown to improve cardiac performance.¹⁷ Perin et al.¹⁷ have shown in a prospective non-randomized open-label study including 21 patients with chronic ischaemic heart failure that myocardial injections of bone marrow mononuclear cells improve cardiac function and reduce detectable ischaemia. This underlines that PCs have beneficial effects in patients with heart failure and especially in patients with ischaemic heart disease. However, to induce such beneficial effects in vivo, higher concentrations of PC have to be generated ex vivo.

Limitations

1. Because of the extensive instrumentation used in our study, we included a limited number of patients only. However, even a large cohort of patients (more than 100 patients) may be not enough to detect slight differences (1%) in PC levels by FACS analysis due to the intrinsic variability of the methodology. More sensitive techniques for PC labelling and detection may lead to different results.
   
2. The method used to determine ‘cardiac uptake’ in the present study (PC aorta–CS) has technical limitations. Nevertheless, the approach has been used in multiple studies regarding cardiac uptake or secretion of neurohormones, etc. in vivo.^18,19 The results obtained from aspirated blood from the aorta and the CS may vary with time and coronary blood flow. Differences in coronary blood flow between groups could have a substantial impact on PC uptake measured at a particular time. In the present study, a ‘steady state’ in PC levels and blood flow measurements were not performed.
   
3. We cannot comment on potential differences in PC differentiation in patients with and without heart failure. The pure quantification of PC may miss such differences.
   
4. We have not determined the uptake of CD34⁺/CD117⁺PC in patients without cardiac disease. Thus, no comment can be made about the physiological situation with regard to CD34⁺/CD117⁺PC uptake. However, such a study would have ethical limitations and was therefore not performed.
   

	Conclusions

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
Moderate-to-severe CHF is not associated with elevated PC levels in the systemic circulation. In addition, a measurable cardiac uptake of CD34⁺ and CD34⁺/CD117⁺PC cannot be demonstrated by FACS analysis in this setting.

	Acknowledgements

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
This work was supported by a grant from ‘Bundesministerium für Bildung und Forschung, Germany’ (BMBF 01 ZZ 0107 and 01 GI 0204).

	References

Top Abstract Introduction Methods Results Discussion Conclusions Acknowledgements References

 
[1] Kocher AA, Schuster MD, Takuma S, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–6.[CrossRef][Web of Science][Medline]

[2] Quaini F, Urbanek K, Beltrami A, et al. Chimerism of the transplanted heart. N Engl J Med 2002; 346: 5–15.[Abstract/Free Full Text]

[3] Zhang YM, Hartzell C, Narlow M, Dudley SC Jr. Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. Circulation 2002; 106: 1294–99.[Abstract/Free Full Text]

[4] Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776–9.[Abstract/Free Full Text]

[5] Leuner S, Aland M, Kahl C, et al. Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Bone Marrow Transplant 1998; 22: 699–706.[CrossRef][Web of Science][Medline]

[6] Goette A, Jentsch-Ullrich K, Lendeckel U, et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiologic role of the atrial natriuretic peptide? Circulation 2003; 108: 2446–9.[Abstract/Free Full Text]

[7] Dyson PG, Ho JQ, Dowse TL, et al. The use of the APAAP technique as a rapid indicator of peripheral blood progenitor cell levels. Pathology 1994; 26: 296–300.[CrossRef][Medline]

[8] Auricchio A, Kloss M, Trautmann SI, et al. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Am J Cardiol 2002; 89: 198–203.[CrossRef][Web of Science][Medline]

[9] Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986; 60: 2020–7.[Abstract/Free Full Text]

[10] Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354–60.[Abstract/Free Full Text]

[11] Warner ED, Dahl CD, Ewy GA. Myocardial injury from transthoracic defibrillator countershock. Arch Pathol 1975; 99: 55–9.[Web of Science][Medline]

[12] Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid transient mobilisation of VEGFR2⁺AC133⁺endothelial precursor cells. Circ Res 2001; 88: 167–74.[Abstract/Free Full Text]

[13] Brenner W, Aicher A, Ecky T, et al. In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 2004; 45: 512–8.[Abstract/Free Full Text]

[14] Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling circulation. 2003; 107: 2134–9.

[15] Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198–202.[Abstract/Free Full Text]

[16] Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209–12.[Abstract/Free Full Text]

[17] Perin EC, Dohmann HFR, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294–302.[Abstract/Free Full Text]

[18] White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 2003; 88: 2376–83.[Free Full Text]

[19] Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72–7.[Abstract/Free Full Text]

CiteULike    Connotea    Del.icio.us    What's this?

This Article Abstract FREE Full Text (PDF) All Versions of this Article: 8/3/157    most recent euj042v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Goette, A. Articles by Auricchio, A. Search for Related Content PubMed PubMed Citation Articles by Goette, A. Articles by Auricchio, A. Social Bookmarking          What's this?

Online ISSN 1532-2092 - Print ISSN 1099-5129

Copyright © 2009 European Heart Rhythm Association of the European Society of Cardiology (ESC)

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics